Request to invoke use of Risdiplam drug.

In a letter dated December 20, 2024, Rajya Sabha MP Haris Beeran urged the Union Health Minister to utilize Section 100(1) of the Patents Act to facilitate the domestic production of Risdiplam, a crucial medication for treating Spinal Muscular Atrophy (SMA), a rare genetic disorder affecting voluntary muscle movement. SMA impacts approximately one in 10,000 newborns in India. For more information read this article.